---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-046358"
form_type: "8-K"
ticker: "CERT"
cik: "0001827090"
company_name: "Certara, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:55:33.416940+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Certara sells Regulatory & Medical Writing business to Veristat for up to $135M

## Summary
- Cash consideration of $100M plus up to $35M earn-out based on future performance.
- Sold business generated $50M revenue and $17M adjusted EBITDA in 2025, employing ~220 people.
- Transaction expected to close in Q2 2026 subject to customary conditions.
- Certara will update 2026 guidance after close; proceeds to be deployed for MIDD platform growth.
- Sale sharpens focus on Model-Informed Drug Development and AI-integrated modeling.

## SEC filing metadata
- accession: 0001104659-26-046358
- form_type: 8-K
- ticker: CERT
- cik: 0001827090
- company_name: Certara, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827090/000110465926046358/0001104659-26-046358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827090/000110465926046358/tm2612400d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-046358
- JSON: https://secwatch.observer/filing/0001104659-26-046358.json
- Plain text: https://secwatch.observer/filing/0001104659-26-046358.txt

## Source-grounded claims
- claim_id: f0e3be701b287018cc0d3ab40197ccda66c53638
  claim: Certara, Inc. entered into Purchase Agreement with Veristat, LLC and certain of its affiliates valued at $100 million (effective 2026-04-21).
  evidence_excerpt: On April 21, 2026, Certara, Inc. (the “Company”), together with certain of its subsidiaries, entered into a Purchase Agreement (the “Purchase Agreement”) with Veristat, LLC and certain of its affiliates (collectively, “Veristat”), pursuant to which the Company agreed to sell its global medical writing and related regulatory services business (the “Business”) to Veristat.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827090/000110465926046358/0001104659-26-046358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.